新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Forest Lab与Trevena制药签署TRV027合作授权协议

Forest Lab与Trevena制药签署TRV027合作授权协议

来源:生物谷 2013-05-09 21:26

2013年5月8日讯 /生物谷BIOON/ --森林实验室(Forest Lab)今天宣布,已与Trevena制药就TRV027的开发签署了合作授权协议。TRV027是一种实验性静脉注射用ADHF药物,最近完成了IIa期临床试验。

Trevena制药称,将于今年年底在急性失代偿心衰(ADHF)患者中,启动一项涉及500例患者的多中心IIb期临床试验。

该项交易的具体条款尚未披露,但所签署的协议包括一笔3000万美元的股权投资,以及在IIb期试验结束后授予Forest Lab有关TRV027在全球范围内的独家开发权利。(生物谷bioon.com)

英文原文:Treven And Forest Labs Reach Deal To Develop TRV027 To Treat Acute Heart Failure

Trevena Inc. and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc. (FRX: Quote), an international pharmaceutical company, announced that they have entered into a collaborative licensing option deal for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

Trevena said it expects to commence a 500-patient multi-center Phase 2b clinical trial in acute decompensated heart failure or ADHF by year end.

Specific terms of the transaction were not disclosed but the agreement includes a $30 million equity investment by Forest in Trevena and the grant by Trevena to Forest Laboratories Holding of an option to exclusively license TRV027 on a worldwide basis following completion of the planned Phase 2b clinical trial which will be funded by Trevena.

The companies will establish a joint development committee to oversee the development of TRV027 with Trevena retaining operational authority during the option period.

Following the exercise of the option, Forest Laboratories Holding will make payments of up to $430 million, depending upon the achievement of future development and commercial milestones, plus royalties, and will have responsibility for the development and commercialization of the product.

As per the terms of the deal, Forest Labs will lead Trevena's $60 million Series C financing round with a $30 million investment. An executive of Forest Laboratories will also join Trevena's Board of Directors. Existing investors also participating in the round are Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company.

Trevena said TRV027 is an experimental intravenous drug for the treatment of acute decompensated heart failure (ADHF), currently in mid-stage clinical trials. It is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R) that combines the proven benefits of angiotensin blockade with new beta-arrestin-mediated biology to preserve cardiac and renal function.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库